SCHEMBL18924893

SCHEMBL18924893

CCC(C)(C)c1c(Cl)cccc1[N+](=O)[O-]

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C19 P33261 3/20 0.44
CYP1A2 P05177 2/20 0.44
CYP2C9 P11712 2/20 0.44
GAA P10253 1/20 0.44
MAPT P10636 1/20 0.43
MAPK1 P28482 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
TDP1 Q9NUW8 3/20 0.43
ALDH1A1 P00352 6/20 0.42
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
LMNA P02545 2/20 0.42
HPGD P15428 1/20 0.41
SMN1; SMN2 Q16637 2/20 0.40
NPC1 O15118 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2D6 P10635 1/20 0.40
RAB9A P51151 1/20 0.40
TSHR P16473 3/20 0.40
GPR35 Q9HC97 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19223460 0.88 CYP1A2 (0.42) CYP2C19CYP1A2CYP2C9GAAMAPT
SCHEMBL6886786 0.83 TDP1 (0.48) CYP2C19CYP1A2CYP2C9GAAMAPT
SCHEMBL6557904 0.79 TDP1 (0.44) CYP2C19CYP1A2CYP2C9GAAMAPT
SCHEMBL19222035 0.78 LMNA (0.39) CYP1A2MAPK1ALDH1A1LMNAHPGD
SCHEMBL4728834 0.76 HPGD (0.46) CYP2C19CYP1A2CYP2C9GAAMAPT
SCHEMBL22043371 0.74 GABRA1 (0.43) ALDH1A1LMNA
SCHEMBL18286925 0.73 TDP1 (0.58) GAAMAPTMAPK1L3MBTL1TDP1
SCHEMBL19222047 0.73 NPSR1 (0.53) TDP1ALDH1A1MEN1KMT2ALMNA
SCHEMBL6889978 0.73 ALDH1A1 (0.51) CYP2C19CYP1A2CYP2C9GAAMAPT
SCHEMBL17297976 0.72 TDP1 (0.60) GAAMAPTMAPK1L3MBTL1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170224665-A1 SELECTIVE HIGH AFFINITY ALFA3BETA4 NICOTINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS Astraea Therapeutics (US) 2017-08-10 US disclosed
US-9670198-B2 Nicotinic acetylcholine receptor modulators ASTRAEA THERAPEUTICS, LLC (US) 2017-06-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170224665-A1 SELECTIVE HIGH AFFINITY ALFA3BETA4 NICOTINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS CHRNA3, CHRNA4, CHRNB3 CYP2C19 2715/4885CYP1A2 911/4885CYP2C9 2907/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.